Skip to main content

 Related scientific articles (all)

Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.

Authors : Habre M, Habre SB, Kourie HR
Year : 2016
Journal : Immunotherapy
Volume : 8
Pages : 1437-1446

Nutrition et prévention du cancer : changer les mentalités

Authors : Awada A
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensit

Authors : Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Sales F, Keilholz U, de Schaetzen G, Testori A
Year : 2016
Journal : Eur J Cancer
Volume : 55
Pages : 111-121

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009

Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

Authors : Lucidi V, Hendlisz A, Van Laethem JL, Donckier V
Year : 2016
Journal : World J Gastroenterol
Volume : 22
Pages : 3937-44

Lorsque le doute s’installe dans la prise de décision thérapeutique : la nécessité de repenser la formation des oncologues

Authors : Canivet D, Peternlj L, Delvaux N, Reynaert C, Razavi D, Libert Y
Year : 2016
Journal : Psycho-oncologie
Volume : 10(4)
Pages : 243-48

Foreword

Authors : Awada A
Year : 2016
Journal : EMJ Oncology
Volume : 41
Pages : 11

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Authors : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Year : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pages : 217-24

Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(6)
Pages : 661-71

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Authors : Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ
Year : 2016
Journal : Cancer Res
Volume : 76
Pages : 264-74

Comparing conventional laparoscopic to robotic-assisted extended pelvic lymph node dissection in men with intermediate and high-risk prostate cancer: a matched-pair analysis.

Authors : Albisinni S, Aoun F, Le Dinh D, Zanaty M, Hawaux E, Peltier A, Van Velthoven R
Year : 2016
Journal : Minerva Urol Nefrol
Volume : 28(25)
Pages : 2941-48

News on the medical treatment of young women with early-stage HER2-negative breast cancer.

Authors : Lambertini M, Poggio F, Vaglica M, Blondeaux E, Del Mastro L
Year : 2016
Journal : Expert Opin Pharmacother
Volume : 17
Pages : 1643-1655

A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.

Authors : Van Velthoven R, Aoun F, Marcelis Q, Albisinni S, Zanaty M, Lemort M, Peltier A, Limani K
Year : 2016
Journal : Prostate Cancer Prostatic Dis
Volume : 19(1)
Pages : 79-83

Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

Authors : Pozdzik A, Beukinga I, Gu-Trantien C, Willard-Gallo K, Nortier J, Pradier O
Year : 2016
Journal : Mediators Inflamm
Volume : 2016
Pages : 7651024

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Authors : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Year : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Authors : Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L
Year : 2016
Journal : World J Clin Infect Dis
Volume : 6(3)
Pages : 37-60

Apport des biopsies ciblées par fusion d’image (us/irmmp) en complément à des biopsies systématisées chez des patients maintenant une suspicion de cancer prostatique après une ou plusieurs séries de biopsies systématisées négatives.

Authors : Roumeguere T, Noël A, Aoun F, Albisinni S, Paesmans M, Van Velthoven R, Peltier A
Year : 2016
Journal : Prog Urol
Volume : 26
Pages : 811-812

Cancer drugs, survival and ethics: a critical look from the inside.

Authors : Piccart-Gebhart M, Pondé N
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000149

Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols.

Authors : Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Elad S, Hamblin MR, Barasch A, Migliorati CA, Milstein DM, Genot-Klastersky MT, Lansaat L, van der Brink R, Arnabat-Dominguez J, van der Molen L, Jacobi I, van Diessen J, de Lange J, Smeele LE, Schubert MM, Bensadoun RJ
Year : 2016
Journal : Support Care Cancer
Volume : 24(6)
Pages : 2793-805

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.

Authors : Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J
Year : 2016
Journal : Br J Cancer
Volume : 114(4)
Pages : 372-80